Pipeline

Principia utilizes its Tailored Covalency® technology to discover and develop safe, effective and convenient oral therapies that have the potential to become standard of care for patients with autoimmune and inflammatory diseases as well as cancer. 

Research
Preclinical
Phase 1
Phase 2
PRN1008: BTK inhibitor / Pemphigus Vulgaris
    
PRN1008: BTK inhibitor / Second Indication
    
PRN1371: FGFR inhibitor / Multiple Cancers
    
PRN2246: BTK inhibitor / CNS, Autoimmune/Inflamm
    
Immunoproteasome Inhibitor: Autoimmune / Inflamm